just to recap .... L‑Dex is validated to detect lymphedema at...

just to recap  ....

• L‑Dex is validated to detect lymphedema at its earliest, subclinical stage
• Detects fluid changes as small as 36 ml (2.4 tablespoons)¹
• Validated against lymphoscintigraphy²
• 80% Sensitive and 90% Specific in detecting subclinical lymphedema following cancer surgery with a 6.5 change from a pre-treatment baseline

• 81% lower incidence of chronic cancer-related lymphedema with BIS L‑Dex monitoring and intervention than with circumference monitoring in a meta-analysis of 67,000 patients⁴
• Statistically lower rates of chronic lymphedema in high-risk patients and short-term and long-term follow-up⁴
• Consistent reduction in lymphedema progression, study after study

81% Lower Rate of Chronic Lymphedema than Circumference Monitoring

This recent meta-analysis confirms that routine monitoring for early detection of lymphedema using ImpediMed’s L-Dex® technology, combined with early intervention, cuts the relative rate of chronic breast cancer-related lymphedema by 81% when compared to circumference monitoring.

The benefit is sustained in high-risk subgroups as well as short-term and long-term follow-up. L-Dex monitoring and intervention studies showed a statistically significant reduction in chronic lymphedema in studies with >50% axillary lymph node dissection (ALND), >40% mastectomy, <2 years follow-up, and>2 years follow-up when compared to circumference studies.


Mayo Clinic

1%  CHURN RATE
100% Renewal Rate


I could go on ....